Results from two phase three clinical trials showed that the experimental weight-loss drug retatrutide may help relieve knee osteoarthritis pain in people with obesity. About two-thirds of participants who received the highest dose recorded a pain reduction of at least 50 percent, alongside a loss of about 25 percent of body weight.
Details of the trial results
The scientific website ScienceDaily reported yesterday, Thursday, citing the results of the two studies published in the New England Journal of Medicine on November 8, that the trials included more than a thousand participants with obesity and knee osteoarthritis. The share of those who recorded a similar reduction in pain among placebo recipients was about 38 percent.
The results also showed improvements in a number of health indicators, including blood pressure, lipid levels and markers of inflammation in the body.
Lead researcher Thomas Schnitzer, a professor at Northwestern University's Feinberg School of Medicine in the United States, explained that weight loss reduces the pressure on the knee joint, which may help relieve pain and improve mobility and the ability to carry out daily activities.
How the drug works
Retatrutide, which is being developed by the American company Eli Lilly, which specializes in pharmaceuticals and the development of medical treatments, is given by injection once a week. It works by activating the receptors of three natural hormones involved in regulating appetite and metabolism, which helps reduce weight.
Open questions and recommendations
Despite the promising results, the drug is still in clinical trials, and it is not yet clear whether it helps slow the progression of arthritis, limit cartilage damage, or reduce the need for knee replacement surgery in the future.
The researchers pointed to the importance of combining balanced nutrition with appropriate physical activity to maintain muscle strength and support knee joint health, stressing the need to follow up with participants and conduct further studies to evaluate the drug's long-term safety and effectiveness.
Knee osteoarthritis is a condition that affects the joint and causes pain, swelling, stiffness and difficulty moving, and it often results from the wearing down of the cartilage that covers the ends of the bones, leading to increased friction between them. Knee osteoarthritis (degenerative joint disease) is one of the most common forms of arthritis, and it is associated with advancing age, excess weight and previous joint injuries.
Source: Syrian Arab News Agency (SANA)

Comments (0)